AC Immune SA (ACIU)
2.60
+0.08
(+3.17%)
USD |
NASDAQ |
Sep 28, 15:01
AC Immune Research and Development Expense (TTM) : 57.87M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 57.87M |
| March 31, 2026 | 64.96M |
| December 31, 2025 | 67.68M |
| September 30, 2025 | 72.38M |
| June 30, 2025 | 72.76M |
| March 31, 2025 | 71.36M |
| December 31, 2024 | 71.00M |
| September 30, 2024 | 69.51M |
| June 30, 2024 | 66.84M |
| March 31, 2024 | 63.11M |
| December 31, 2023 | 60.76M |
| September 30, 2023 | 59.96M |
| June 30, 2023 | 60.80M |
| March 31, 2023 | 61.83M |
| December 31, 2022 | 63.21M |
| September 30, 2022 | 69.34M |
| June 30, 2022 | 70.92M |
| March 31, 2022 | 69.72M |
| December 31, 2021 | 68.06M |
| September 30, 2021 | 63.88M |
| June 30, 2021 | 64.29M |
| Date | Value |
|---|---|
| March 31, 2021 | 62.52M |
| December 31, 2020 | 63.52M |
| September 30, 2020 | 60.68M |
| June 30, 2020 | 55.45M |
| March 31, 2020 | 54.83M |
| December 31, 2019 | 50.75M |
| September 30, 2019 | 48.11M |
| June 30, 2019 | 47.95M |
| March 31, 2019 | 45.72M |
| December 31, 2018 | 44.51M |
| September 30, 2018 | 42.43M |
| June 30, 2018 | 39.30M |
| March 31, 2018 | 35.67M |
| December 31, 2017 | 32.59M |
| September 30, 2017 | 29.45M |
| June 30, 2017 | 28.93M |
| March 31, 2017 | 27.87M |
| December 31, 2016 | 25.88M |
| September 30, 2016 | 24.59M |
| June 30, 2016 | 21.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Precigen, Inc. | 31.01M |
| Basilea Pharmaceutica AG | 153.18M |
| Santhera Pharmaceuticals Holding AG | 26.72M |
| Aldeyra Therapeutics, Inc. | 15.63M |
| BeOne Medicines Ltd. | 2.220B |